Table 2 Haematologic and non-haematologic abnormalities and infections between + 24 and + 100 days posttransplant
AI focus group (n = 110) | Co-variate-matched controls (n = 252) | p-value a | |
|---|---|---|---|
Haematologic abnormalities, n (%) | |||
Severe anaemia (haemoglobin <80 g/L) | 67 (61) | 140 (56) | 0.36 |
Severe neutropenia (neutrophils <500/μL) | 28 (25) | 62 (25) | 0.90 |
Severe thrombocytopenia (platelets <20000/μL) | 34 (31) | 108 (43) | 0.04 |
Non-haematologic, n (%) | |||
Headache | 13 (12) | 17 (7) | 0.15 |
Dizziness | 9 (8) | 17 (7) | 0.66 |
Diarrhoea | 28 (25) | 77 (31) | 0.38 |
Oedema | 8 (7) | 29 (12) | 0.26 |
Severe hypercholesterolaemia (total cholesterol >17.1mmol/L) | 0 (0) | 1 (0.4) | >0.99 |
High alanine transaminase level ( >120 U/L) | 16 (15) | 58 (23) | 0.07 |
High aspartate transaminase level ( >105 U/L) | 8 (7) | 53 (21) | 0.001 |
High total bilirubin ( >63 μmol/L) | 5 (5) | 21 (8) | 0.27 |
Petechiae, bruises, or purpura | 5 (5) | 28 (11) | 0.05 |
Haemorrhagic cystitis | 20 (18) | 78 (31) | 0.01 |
Bleeding at other loci (oropharynx, nose, lung, or digestive tract) | 6 (5) | 21 (8) | 0.39 |
Cardiac event(s) | 7 (6) | 11 (4) | 0.44 |
Thrombosis | 0 (0) | 3 (1) | 0.56 |
Infection, n (%) | |||
CMV viraemia (DNA ≥5000 copies/ml) * | 7 (6) | 112 (44) | <0.001 |
Pneumonia | 4 (4) | 19 (8) | 0.24 |
Urinary tract infection | 24 (22) | 70 (28) | 0.24 |
Infection at other loci (oropharynx, skin, soft tissue, or perianal region) | 13 (12) | 31 (12) | >0.99 |
